Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, announces the acquisition of a majority stake in DeuterOncology, a Belgium-based company developing DO-2, a third-generation MET kinase inhibitor for patients with MET-altered cancers. The asset was systematically identified, evaluated, and advanced to acquisition through the Pathos Foundry platform. DO-2 has completed Phase 1 dose escalation across eight clinical sites in the Netherlands, Belgium, and France.
Read the full article: Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform //
Source: https://www.globenewswire.com/news-release/2026/05/06/3288745/0/en/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-next-generation-met-inhibitor-identified-by-pathos-foundry-platform.html